Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 30 May 2018 Status changed from recruiting to active, no longer recruiting.
- 21 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 21 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.